NeuroMetrix Inc represents values of innovation, quality, and patient-centered care in the field of neurology and medical technology. The company is committed to developing advanced solutions that improve the lives of patients suffering from chronic conditions, particularly those related to nerve disorders. With a customer-centric approach, NeuroMetrix Inc aims to provide cutting-edge diagnostic and therapeutic products that enable healthcare professionals to deliver more accurate diagnoses and personalized treatments. By combining medical expertise with technological advancements, NeuroMetrix Inc is dedicated to enhancing the well-being and outcomes of individuals battling neurological conditions.

NeuroMetrix Inc is primarily present in the United States, focusing on the domestic market.

NeuroMetrix Inc, a renowned company in the medical device industry, has achieved several significant milestones throughout its history. The company developed and launched the innovative wearable technology device, Quell, which is designed to provide non-invasive pain relief and enhance the quality of life for individuals suffering from chronic pain. NeuroMetrix Inc also obtained FDA clearance for numerous products, including SENSUS, a wearable pain therapy device. Furthermore, the company has forged strategic partnerships, expanding its market reach and enhancing its product portfolio. With its dedication to innovation and commitment to improving pain management, NeuroMetrix Inc continues to lead the way in the medical device industry and bring relief to countless individuals worldwide.

NeuroMetrix Inc. is a renowned medical technology company with a notable background and history. Established in 1996, the company focuses on developing innovative solutions for the diagnosis and monitoring of chronic neurological diseases and disorders. With a strong emphasis on research and development, NeuroMetrix has pioneered breakthroughs in the field of neurodiagnostics, particularly in the areas of neuropathy and neurodegenerative conditions. The company's flagship product, Quell, is a wearable therapeutic device that utilizes neurostimulation technology to provide relief from chronic pain. Over the years, NeuroMetrix Inc. has consistently demonstrated its commitment to improving patients' lives through groundbreaking advancements in neurological healthcare.

The main competitors of NeuroMetrix Inc in the market are companies like Medtronic plc, Abbott Laboratories, and Becton, Dickinson and Company.

NeuroMetrix Inc is primarily active in the medical technology industry.

The business model of NeuroMetrix Inc revolves around developing and commercializing innovative medical devices for the diagnosis and treatment of neurological disorders. NeuroMetrix primarily focuses on the development of wearable neurostimulation devices to address chronic pain management and peripheral neuropathy. The company's flagship product is Quell, a wearable pain relief device that utilizes neurostimulation technology. By leveraging advanced sensor and digital health technologies, NeuroMetrix aims to improve patient outcomes and quality of life. With a strong emphasis on researching and developing non-invasive solutions, NeuroMetrix aims to provide effective and accessible solutions for neurological disorders.

Коефициентът на цена спрямо печалбата (КЦП) на NeuroMetrix е 0,10.

Коефициентът на цена към оборот (KUV) на NeuroMetrix е 0,10.

AlleAktien качественият резултат за NeuroMetrix е 3/10.

очаквана NeuroMetrix оборотът е 39,23 млн. USD.

очаквана NeuroMetrix печалба е 36,18 млн. USD.

NeuroMetrix Inc is an American company specialized in the development and marketing of medical devices for the diagnosis and treatment of neurological disorders. The company was founded in 1996 and is headquartered in Woburn, Massachusetts. NeuroMetrix's business model is focused on developing and establishing innovative medical products in the market. The company is divided into three main divisions: diagnostics, therapy, and wellness. The diagnostics division of NeuroMetrix includes products such as the NC-stat System, a portable device that performs peripheral nervous system diagnostics. The system is used by doctors and healthcare providers to detect and monitor diseases such as diabetic neuropathy. The therapy division of NeuroMetrix focuses on the treatment of pain and other neurological disorders. The company offers products such as the SENSUS Pain Therapy Device, which is used to relieve chronic pain. The SENSUS device stimulates the peripheral nerves at low frequencies to reduce pain in the back, leg, ankle, foot, and knee areas. The wellness division of NeuroMetrix includes products such as the Quell System, a wearable device worn on the ankle that helps reduce pain and insomnia. The Quell System uses a neurological method to stimulate the body's natural pain relief mechanisms. NeuroMetrix has introduced its products in the US and internationally. The company works closely with healthcare providers and insurance companies to ensure that its products are covered by insurance and can be used in practice. Another important aspect of NeuroMetrix's business model is continuous research and development. The company constantly invests in new technologies and products to strengthen its position in the medical device industry. Additionally, the company collaborates closely with clinicians and scientists to identify and develop new medical applications for its products. In addition to its innovative product range, NeuroMetrix places great emphasis on high product quality and customer satisfaction. The company works closely with customers to ensure that its products meet their needs and requirements. Furthermore, NeuroMetrix provides excellent customer support and training for medical personnel to ensure the effective and safe use of its products. In summary, NeuroMetrix Inc's business model is based on the successful marketing of medical diagnosis and treatment devices through innovative technologies and close collaboration with customers and clinicians. The company focuses on constant product development and works closely with insurance companies and healthcare providers to ensure that its products are used by doctors and patients in practice.

NeuroMetrix разпределя дивидента от 0 USD на плащания годишно.

Дивидентата за NeuroMetrix в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на NeuroMetrix е US6412558073.

WKN на NeuroMetrix е A2PVRC.

Тикерът на NeuroMetrix е NURO.

През последните 12 месеца NeuroMetrix изплати дивиденда в размер на 1728,00 USD . Това съответства на дивидендна доходност от около 47 998,67 %. За следващите 12 месеца се очаква NeuroMetrix да изплати дивиденда в размер на 0 USD.

Дивидентната доходност на NeuroMetrix в момента е 47 998,67 %.

NeuroMetrix изплаща дивидент на тримесечие. Той се разпределя в месеците .

NeuroMetrix платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 USD. Това съответства на дивидентна доходност от 0 %.

NeuroMetrix се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от NeuroMetrix на 13.04.2007 г. в размер на 0,15 USD, трябваше да притежавате акцията в портфейла си преди Ex-деня на 28.03.2007 г..

Последното дивидентно плащане беше извършено на 13.04.2007 г..

През година 2023 NeuroMetrix изплати 0 USD под формата на дивиденти.

Дивидентите от NeuroMetrix се изплащат в USD.